Human Immunodeficiency Virus Types 1 and 2 Exhibit Comparable Sensitivities to Zidovudine and Other Nucleoside Analog Inhibitors In Vitro | Zendy

Robert A. Smith | Zendy; Geoffrey S. Gottlieb | Zendy; Donovan J. Anderson | Zendy; Crystal L. Pyrak | Zendy; Bradley D. Preston | Zendy

Open Access

Human Immunodeficiency Virus Types 1 and 2 Exhibit Comparable Sensitivities to Zidovudine and Other Nucleoside Analog Inhibitors In Vitro

Author(s) -

Robert A. Smith,

Geoffrey S. Gottlieb,

Donovan J. Anderson,

Crystal L. Pyrak,

Bradley D. Preston

Publication year - 2007

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01004-07

Subject(s) - zidovudine , nucleoside analogue , nucleoside , reverse transcriptase , virology , in vitro , nucleotidyltransferase , virus , human immunodeficiency virus (hiv) , biology , viral disease , rna , biochemistry , gene

Using an indicator cell assay that directly quantifies viral replication, we show that human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2, respectively) exhibit similar sensitivities to 3′-azido-3′-deoxythymidine (zidovudine) as well as other nucleoside analog inhibitors of reverse transcriptase. These data support the use of nucleoside analogs for antiviral therapy of HIV-2 infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research